SEQUENCE LISTING

<110> Abbott Laboratories, Inc.
Morgan-Lappe, Susan E

<120> THERAPEUTIC DLL4 BINDING PROTEINS

<130> 10289.WO.01

<150> US 61/238,152
<151> 2009-08-29

<150> US 61/261,728
<151> 2009-11-16

<160> 377

<170> PatentIn version 3.5

<210> 1
<211> 121
<212> PRT
<213> Homo sapiens

<400> 1

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 2
<211> 330
<212> PRT
<213> Homo sapiens

<400> 2

Ala Ser Thr Lys Gly Pro Ser Val Phe Phe Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

```
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
    290                 295                 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305                 310                 315                 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
                325                 330
```

<210> 3
<211> 330
<212> PRT
<213> Artificial Sequence

<220>
<223> IgG1 constant region mutant

<400> 3

```
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1               5                   10                  15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
            20                  25                  30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
        35                  40                  45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
    50                  55                  60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65                  70                  75                  80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
                85                  90                  95

Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
            100                 105                 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
        115                 120                 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
    130                 135                 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145                 150                 155                 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
                165                 170                 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
```

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 4
<211> 106
<212> PRT
<213> Homo sapiens

<400> 4

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
35 40 45

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85 90 95

Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 5
<211> 105
<212> PRT
<213> Homo sapiens

<400> 5

Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
1 5 10 15

Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
20 25 30

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
35 40 45

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
50 55 60

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
65 70 75 80

His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
85 90 95

Lys Thr Val Ala Pro Thr Glu Cys Ser
100 105

<210> 6
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-70/JH6 FR1 heavy chain acceptor sequence

<400> 6

Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser
20 25 30

<210> 7
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-70/JH6 FR2 heavy chain acceptor sequence

<400> 7

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala
1 5 10

<210> 8
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-70/JH6 FR3 heavy chain acceptor sequence

<400> 8

Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr
1 5 10 15

Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
20 25 30

<210> 9
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-70/JH6 FR4 heavy chain acceptor sequence

<400> 9

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
1 5 10

<210> 10
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-26/JH6 FR1 heavy chain acceptor sequence

<400> 10

Glu Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser
20 25 30

<210> 11
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH2-26/JH6 FR3 heavy chain acceptor sequence

<400> 11

Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val Val Leu Thr
1 5 10 15

Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
20 25 30

<210> 12
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-72/JH6 FR1 heavy chain acceptor sequence

<400> 12

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
20 25 30

<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-72/JH6 FR2 heavy chain acceptor sequence

<400> 13

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly
1 5 10

<210> 14
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-72/JH6 FR3 heavy chain acceptor sequence

<400> 14

Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln
1 5 10 15

Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 15
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-21/JH6 FR1 heavy chain acceptor sequence

<400> 15

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
20 25 30

<210> 16
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-21/JH6 FR2 heavy chain acceptor sequence

<400> 16

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
1 5 10

<210> 17
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH3-21/JH6 FR3 heavy chain acceptor sequence

<400> 17

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln
1 5 10 15

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 18
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1-69/JH6 FR1 heavy chain acceptor sequence

<400> 18

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
20 25 30

<210> 19
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1-69/JH6 FR2 heavy chain acceptor sequence

<400> 19

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
1 5 10

<210> 20
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1-69/JH6 FR3 heavy chain acceptor sequence

<400> 20

Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 21
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1-18/JH6 FR1 heavy chain acceptor sequence

<400> 21

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> 22
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> VH1-18/JH6 FR3 heavy chain acceptor sequence

<400> 22

Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 23
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> B3/JK4 FR1 light chain acceptor sequence

<400> 23

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys
20

<210> 24
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> B3/JK4 FR2 light chain acceptor sequence

<400> 24

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 25
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> B3/JK4 FR3 light chain acceptor sequence

<400> 25

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
20 25 30

<210> 26
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> B3/JK4 FR4 light chain acceptor sequence

<400> 26

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
1 5 10

<210> 27
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> L2/JK4 FR1 light chain acceptor sequence

<400> 27

Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys
20

<210> 28
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> L2/JK4 FR2 light chain acceptor sequence

<400> 28

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr
1 5 10 15

<210> 29
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> L2/JK4 FR3 light chain acceptor sequence

<400> 29

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
20 25 30

<210> 30
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> L15/JK4 FR1 light chain acceptor sequence

<400> 30

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 31
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> L15/JK4 FR2 light chain acceptor sequence

<400> 31

Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile Tyr
1 5 10 15

<210> 32
<211> 32
<212> PRT

<213> Artificial Sequence

<220>
<223> L15/JK4 FR3 light chain acceptor sequence

<400> 32

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> 33
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> L5/JK4 FR1 light chain acceptor sequence

<400> 33

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> 34
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> L5/JK4 FR2 light chain acceptor sequence

<400> 34

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 35
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59 FR1 heavy chain acceptor sequence

<400> 35

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
20 25 30

<210> 36
<211> 14
<212> PRT

<213> Artificial Sequence

<220>
<223> IGHV4-59 FR2 heavy chain acceptor sequence

<400> 36

Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
1 5 10

<210> 37
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59 FR3 heavy chain acceptor sequence

<400> 37

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys
1 5 10 15

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 38
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59/JH FR4 heavy chain acceptor sequence

<400> 38

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 39
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-66 FW1 heavy chain acceptor sequence

<400> 39

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser
20 25 30

<210> 40
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-66 FW2 heavy chain acceptor sequence

<400> 40

Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly
1 5 10

<210> 41
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-66 FW3 heavy chain acceptor sequence

<400> 41

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe Tyr Leu Gln
1 5 10 15

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 42
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-66/JH FW4 heavy chain acceptor sequence

<400> 42

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 43
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59 FR1 heavy chain acceptor sequence

<400> 43

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
20 25 30

<210> 44
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59 FR2 heavy chain acceptor sequence

<400> 44

Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly

1 5 10

<210> 45
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59 FR3 heavy chain acceptor sequence

<400> 45

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Tyr Leu Lys
1 5 10 15

Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> 46
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV4-59/JH FR4 heavy chain acceptor sequence

<400> 46

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> 47
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV5-51 FR1 heavy chain acceptor sequence

<400> 47

Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
1 5 10 15

Ser Leu Lys Ile Ser Cys Lys Val Ser Gly Gly Ser Ile Ser
20 25 30

<210> 48
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV5-51 FR2 heavy chain acceptor sequence

<400> 48

Trp Ile Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Ile Gly
1 5 10

<210> 49

<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV5-51 FR3 heavy chain acceptor sequence

<400> 49

Gln Val Thr Ile Ser Val Asp Thr Ser Phe Asn Thr Phe Phe Leu Gln
1 5 10 15

Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg
20 25 30

<210> 50
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV5-51/JH FR4 heavy chain acceptor sequence

<400> 50

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1 5 10

<210> 51
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV2-70 FR1 heavy chain acceptor sequence

<400> 51

Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser
20 25 30

<210> 52
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV2-70 FR2 heavy chain acceptor sequence

<400> 52

Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
1 5 10

<210> 53
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV2-70 FR3 heavy chain acceptor sequence

<400> 53

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Val Leu Thr
1 5 10 15

Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg
20 25 30

<210> 54
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV2-70/JH FR4 heavy chain acceptor sequence

<400> 54

Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
1 5 10

<210> 55
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-15 FR1 heavy chain acceptor sequence

<400> 55

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg
20 25 30

<210> 56
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-15 FR2 heavy chain acceptor sequence

<400> 56

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1 5 10

<210> 57
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-15 FR3 heavy chain acceptor sequence

<400> 57

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
1 5 10 15

Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
20 25 30

<210> 58
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-15/JH FR4 heavy chain acceptor sequence

<400> 58

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1 5 10

<210> 59
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-43 FR1 heavy chain acceptor sequence

<400> 59

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly
20 25 30

<210> 60
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-43 FR2 heavy chain acceptor sequence

<400> 60

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1 5 10

<210> 61
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-43 FR3 heavy chain acceptor sequence

<400> 61

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
1 5 10 15

Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys
20 25 30

<210> 62
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGHV3-43/JH FR4 heavy chain acceptor sequence

<400> 62

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
1 5 10

<210> 63
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 63

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys
20

<210> 64
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 64

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 65
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 65

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
20 25 30

<210> 66
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 66

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
1 5 10

<210> 67
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 67

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys
20

<210> 68
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 68

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 69
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 69

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
20 25 30

<210> 70
<211> 10
<212> PRT

<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 70

Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
1 5 10

<210> 71
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 71

Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr
1 5 10 15

Ala Ser Ile Thr Cys
20

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 72

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 73
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 73

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Pro Met Asp Glu Ala Asp Tyr Tyr Cys
20 25 30

<210> 74
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 74

Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
1 5 10

<210> 75
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 75

Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys
20

<210> 76
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 76

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 77
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 77

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
20 25 30

<210> 78
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 78

Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly

1 5 10

<210> 79
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV6D-21 FR1 light chain acceptor sequence

<400> 79

Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1 5 10 15

Glu Lys Val Thr Ile Thr Cys
20

<210> 80
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV6D-21 FR2 light chain acceptor sequence

<400> 80

Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile Tyr
1 5 10 15

<210> 81
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV6D-21 FR3 light chain acceptor sequence

<400> 81

Gly Val Pro Ser Arg Phe Ser Gly Ser Asn Ser Gly Asp Asp Ala Thr
1 5 10 15

Leu Thr Ile Asn Ser Leu Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys
20 25 30

<210> 82
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV6D-21/JK FR4 light chain acceptor sequence

<400> 82

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
1 5 10

<210> 83

<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV3D-15 FR1 light chain acceptor sequence

<400> 83

Glu Tyr Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys
20

<210> 84
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV3D-15 FR2 light chain acceptor sequence

<400> 84

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Val Ile Tyr
1 5 10 15

<210> 85
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV3D-15 FR3 light chain acceptor sequence

<400> 85

Asp Ile Pro Ala Arg Phe Ser Gly Ser Asn Ser Gly Asp Glu Ala Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys
20 25 30

<210> 86
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV3D-15/JK FR4 light chain acceptor sequence

<400> 86

Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
1 5 10

<210> 87
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV4-1 FR1 light chain acceptor sequence

<400> 87

Asp Tyr Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys
20

<210> 88
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV4-1 FR2 light chain acceptor sequence

<400> 88

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Val Ile Tyr
1 5 10 15

<210> 89
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV4-1 FR3 light chain acceptor sequence

<400> 89

Gly Ile Pro Asp Arg Phe Ser Gly Ser Asn Ser Gly Asp Asp Ala Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
20 25 30

<210> 90
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> IGKV4-1/JK FR4 light chain acceptor sequence

<400> 90

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
1 5 10

<210> 91
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 91

Leu Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys
20

<210> 92
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 92

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 93
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 93

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
20 25 30

<210> 94
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 94

Phe Gly Gly Gly Thr Lys Val Thr Val Leu
1 5 10

<210> 95
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR1 light chain acceptor sequence

<400> 95

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys
20

<210> 96
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR2 light chain acceptor sequence

<400> 96

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
1 5 10 15

<210> 97
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1 FR3 light chain acceptor sequence

<400> 97

Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
1 5 10 15

Leu Thr Ile Ser Gly Thr Gln Thr Met Asp Glu Ala Asp Tyr Leu Cys
20 25 30

<210> 98
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> IGLV3-1/JL FR4 light chain acceptor sequence

<400> 98

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
1 5 10

<210> 99
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H1 consensus sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is S or N

<220>
<221> MISC_FEATURE
<222> (2)..(2)

<223> X is S, G or N

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is S, N, T, G or R

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is Y or H

<400> 99

Xaa Xaa Xaa Tyr Xaa Trp Gly
1 5

<210> 100
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H2 consensus sequence

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is Y, N or S

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is T, N, A, I, S or R

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is S, N, T or G

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> X is S, N, D or G

<400> 100

Asp Ile Xaa Tyr Xaa Gly Xaa Thr Tyr Tyr Asn Pro Ser Leu Lys Xaa
1 5 10 15

<210> 101
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H3 consensus sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is E, Y, F, Q, W, L or A

<220>

<221> MISC_FEATURE
<222> (2)..(2)
<223> X is D, A, S, G, V, E or N

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is V, M, L, P or A

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is I, A, P, R, S, K, Q, V, G, M, or E

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is L, Y, F or M

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is R, G, S, Q or A

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is G, A or S

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X is S, A, L, V, R or G

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> X is Y, D, S, N, H, E, R, L, P, C, I, M, T, Q or K

<400> 101

Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Asp Xaa
1 5 10

<210> 102
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-L1 consensus sequence

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is Q, E or D

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is R, S, G, M, K, L or T

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is D or E

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is A or V

<400> 102

Ser Gly Xaa Xaa Leu Gly Xaa Lys Tyr Xaa Ser
1 5 10

<210> 103
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-L2 consensus sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is E or Q

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is S, L, T, A, E or F

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is K, T, E, N, Q, S, or M

<400> 103

Xaa Asp Xaa Xaa Arg Pro Ser
1 5

<210> 104
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-L3 consensus sequence

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is R, S, M, E, N, G or K

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is D or E

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is T, V, A, S or M

<220>
<221> MISC_FEATURE

<222> (8)..(8)
<223> X is G, A or C

<400> 104

Gln Ala Trp Asp Xaa Xaa Xaa Xaa Val
1 5

<210> 105
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H1 consensus sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is S, N or D

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is H or Y

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is S or H

<400> 105

Xaa Xaa Trp Met Xaa
1 5

<210> 106
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H2 consensus sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X is I, D, M or T

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is Y, N, S, Q, V, T, H or D

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is S, R, I, T, G, K, H or N

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is N, Y, S, I or T

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> X is K, M, N, Q, E, T, R, S, A or L

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is Y, D or E

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> X is S or Y

<400> 106

Xaa Ile Ser Xaa Asp Gly Xaa Xaa Xaa Xaa Xaa Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 107
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-H3 consensus sequence

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is G, A or R

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is G, S or A

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is V or M

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is F, L, Y or M

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is I, S or L

<400> 107

Ala Xaa Gly Xaa Asn Xaa Gly Xaa Asp Xaa
1 5 10

<210> 108
<211> 11
<212> PRT

<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-L1 consensus sequence

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is A or G

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is K, N, L, Q, M, E, S, T, G or D

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is T, S, N, A, G or E

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is K, Q, N or R

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> X is V or I

<400> 108

Ser Xaa Asp Xaa Leu Gly Xaa Xaa Tyr Xaa Ser
1 5 10

<210> 109
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody CDR-L2 consensus sequence

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X is A, G, W, S or D

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> X is K, M, Q, N, L, T, I or E

<400> 109

Gln Asp Xaa Xaa Arg Pro Ser
1 5

<210> 110
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody CDR-L3 consensus sequence

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X is S or A

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X is R, S, Q, P, A, V, W or M

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> X is S, G, I, N, R or T

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> X is D or G

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> X is V, A, P or E

<400> 110

Gln Ser Trp Asp Xaa Xaa Xaa Xaa Val
1 5

<210> 111
<211> 106
<212> PRT
<213> Homo sapiens

<400> 111

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Arg Val Thr Val Leu
100 105

<210> 112
<211> 119
<212> PRT
<213> Homo sapiens

<400> 112

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Ile Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 113
<211> 106
<212> PRT
<213> Homo sapiens

<400> 113

Leu Pro Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65 70 75 80

Asp Glu Ala Asp Tyr Leu Cys Gln Ser Trp Asp Arg Ser Asp Val Val

85 90 95

Phe Gly Gly Gly Thr Lys Val Thr Val Leu
100 105

<210> 114
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> mutations of antibody E9 VH sequence

<220>
<221> MISC_FEATURE
<222> (30)..(30)
<223> X is S, N, G or R

<220>
<221> MISC_FEATURE
<222> (31)..(31)
<223> X is S or N

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> X is S, G or N

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> X is S, N, T, G or R

<220>
<221> MISC_FEATURE
<222> (42)..(42)
<223> X is P, S or L

<220>
<221> MISC_FEATURE
<222> (54)..(54)
<223> X is Y or N

<220>
<221> MISC_FEATURE
<222> (56)..(56)
<223> X is T, N, A, I, S or R

<220>
<221> MISC_FEATURE
<222> (58)..(58)
<223> X is S, N, T or G

<220>
<221> MISC_FEATURE
<222> (67)..(67)
<223> X is S, N, D or G

<220>
<221> MISC_FEATURE
<222> (90)..(90)
<223> X is A or E

<220>
<221> MISC_FEATURE

<222> (100)..(100)
<223> X is E, Y, F, Q, W, L or A

<220>
<221> MISC_FEATURE
<222> (101)..(101)
<223> X is D, A, S, G, V, E or N

<220>
<221> MISC_FEATURE
<222> (102)..(102)
<223> X is V, M, L or P

<220>
<221> MISC_FEATURE
<222> (103)..(103)
<223> X is I, A, P, R, S, K, Q, V, G, M or E

<220>
<221> MISC_FEATURE
<222> (104)..(104)
<223> X is L, Y, F or M

<220>
<221> MISC_FEATURE
<222> (105)..(105)
<223> X is R, G, S, Q or A

<220>
<221> MISC_FEATURE
<222> (107)..(107)
<223> X is G, S or A

<220>
<221> MISC_FEATURE
<222> (108)..(108)
<223> X is S, A, L, V or R

<220>
<221> MISC_FEATURE
<222> (110)..(110)
<223> X is Y, D, S, N, H, E, R, L, P, C, I or M

<400> 114

```
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                  10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Xaa Xaa Xaa
            20                  25                  30

Xaa Tyr Tyr Trp Gly Trp Ile Arg Gln Xaa Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Xaa Tyr Xaa Gly Xaa Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Xaa Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Xaa Asp Thr Ala Val Tyr Tyr
                85                  90                  95
```

Cys Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Asp Xaa Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 115
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> mutations of antibody E9 VL sequence

<220>
<221> MISC_FEATURE
<222> (25)..(25)
<223> X is Q, E or D

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> X is R, S, G, M, K, L or T

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> X is D or E

<220>
<221> MISC_FEATURE
<222> (32)..(32)
<223> X is A or V

<220>
<221> MISC_FEATURE
<222> (49)..(49)
<223> X is E or Q

<220>
<221> MISC_FEATURE
<222> (51)..(51)
<223> X is S, L, T, A, E or F

<220>
<221> MISC_FEATURE
<222> (52)..(52)
<223> X is K, T, E, N, Q, S or M

<220>
<221> MISC_FEATURE
<222> (79)..(79)
<223> X is P or A

<220>
<221> MISC_FEATURE
<222> (92)..(92)
<223> X is R, S, M, E, N or K

<220>
<221> MISC_FEATURE
<222> (93)..(93)
<223> X is D or E

<220>
<221> MISC_FEATURE
<222> (94)..(94)
<223> X is T, V, A, S or M

<220>
<221> MISC_FEATURE
<222> (95)..(95)
<223> X is G, A or C

<220>
<221> MISC_FEATURE
<222> (99)..(99)
<223> X is Y or S

<220>
<221> MISC_FEATURE
<222> (102)..(102)
<223> X is R or K

<400> 115

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Xaa Xaa Leu Gly Xaa Lys Tyr Xaa
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Xaa Asp Xaa Xaa Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Xaa Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Xaa Xaa Xaa Xaa Val
85 90 95

Phe Gly Xaa Gly Thr Xaa Val Thr Val Leu
100 105

<210> 116
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> affinity matured DLL4 antibody E9.4 VH region

<400> 116

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Tyr Asp Val Ser Leu Gly Gly Ser Ser Asp His Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 117
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 CDR-H1

<400> 117

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 118
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 CDR-H2

<400> 118

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 119
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 CDR-H3

<400> 119

Tyr Asp Val Ser Leu Gly Gly Ser Ser Asp His
1 5 10

<210> 120
<211> 121

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 VH region

<400> 120

```
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                  10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Ala Val Pro Leu Gly Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 121
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-H1

<400> 121

```
Ser Ser Ser Tyr Tyr Trp Gly
1               5
```

<210> 122
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-H2

<400> 122

```
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                  10                  15
```

<210> 123
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-H3

<400> 123

Glu Ala Val Pro Leu Gly Gly Gly Ser Asp Tyr
1 5 10

<210> 124
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 VH region

<400> 124

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Ser
20 25 30

Arg Tyr His Trp Gly Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 125
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-H1

<400> 125

Asn Ser Arg Tyr His Trp Gly
1 5

<210> 126
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-H2

<400> 126

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 127
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-H3

<400> 127

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1 5 10

<210> 128
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 VH region

<400> 128

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Glu Ala Ile Leu Gly Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 129
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-H1

<400> 129

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 130
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-H2

<400> 130

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 131
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-H3

<400> 131

Glu Glu Ala Ile Leu Gly Gly Gly Ser Asp Tyr
1 5 10

<210> 132
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 VH region

<400> 132

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

```
Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 133
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-H1

<400> 133

```
Ser Ser Gly Tyr Tyr Trp Gly
1               5
```

<210> 134
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-H2

<400> 134

```
Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
```

<210> 135
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-H3

<400> 135

```
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
```

<210> 136
<211> 121
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.19 VH region

<400> 136

```
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                  10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Phe Asp Val Ser Leu Gly Gly Gly Ser Asp Thr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 137
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-H1

<400> 137

```
Ser Ser Ser Tyr Tyr Trp Gly
1               5
```

<210> 138
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-H2

<400> 138

```
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                  10                  15
```

<210> 139
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-H3

<400> 139

Phe Asp Val Ser Leu Gly Gly Gly Ser Asp Thr
1 5 10

<210> 140
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 VH region

<400> 140

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Ser
20 25 30

Arg Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 141
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-H1

<400> 141

Asn Ser Arg Tyr His Trp Gly
1 5

<210> 142
<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-H2

<400> 142

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Gly
1 5 10 15

<210> 143
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-H3

<400> 143

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1 5 10

<210> 144
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 VH region

<400> 144

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Asn Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 145
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-H1

<400> 145

Ser Ser Gly Tyr Tyr Trp Gly
1 5

<210> 146
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-H2

<400> 146

Asp Ile Asn Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 147
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-H3

<400> 147

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1 5 10

<210> 148
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 VH region

<400> 148

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Arg Asn Ser
20 25 30

Arg Tyr His Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Gly Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 149
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-H1

<400> 149

Asn Ser Arg Tyr His Trp Gly
1 5

<210> 150
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-H2

<400> 150

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Gly
1 5 10 15

<210> 151
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-H3

<400> 151

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1 5 10

<210> 152
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 VH region

<400> 152

```
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Gly Val Pro Leu Gly Gly Gly Ala Asp Lys Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 153
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-H1

<400> 153

```
Ser Ser Ser Tyr Tyr Trp Gly
1               5
```

<210> 154
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-H2

<400> 154

```
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
```

<210> 155
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-H3

<400> 155

Glu Gly Val Pro Leu Gly Gly Gly Ala Asp Lys
1 5 10

<210> 156
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 VH region

<400> 156

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 157
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 CDR-H1

<400> 157

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 158
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.71 CDR-H2

<400> 158

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 159
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 CDR-H3

<400> 159

Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys
1 5 10

<210> 160
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 VH region

<400> 160

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 161
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-H1

<400> 161

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 162
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-H2

<400> 162

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 163
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-H3

<400> 163

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1 5 10

<210> 164
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.16 VH region

<400> 164

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

```
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95


Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110


Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120


<210>  165
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DLL4 antibody E9.16 CDR-H1

<400>  165

Ser Ser Ser Tyr Tyr Trp Gly
1               5


<210>  166
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DLL4 antibody E9.16 CDR-H2

<400>  166

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15


<210>  167
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DLL4 antibody E9.16 CDR-H3

<400>  167

Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10


<210>  168
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DLL4 antibody E9.38 VH region

<400>  168

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                   10                  15
```

```
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 169
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-H1

<400> 169

```
Ser Ser Ser Tyr Tyr Trp Gly
1               5
```

<210> 170
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-H2

<400> 170

```
Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
```

<210> 171
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-H3

<400> 171

```
Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr
1               5                   10
```

<210> 172
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B VH region

<400> 172

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Asn Tyr Asn Gly Asn Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Asp Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 173
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-H1

<400> 173

Ser Ser Asn Tyr Tyr Trp Gly
1 5

<210> 174
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-H2

<400> 174

Asp Ile Asn Tyr Asn Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 175
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-H3

<400> 175

Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Asp
1 5 10

<210> 176
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F VH region

<400> 176

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 177
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-H1

<400> 177

Ser Gly Ser Tyr Tyr Trp Gly
1 5

<210> 178
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-H2

<400> 178

Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 179
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-H3

<400> 179

Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser
1 5 10

<210> 180
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H VH region

<400> 180

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Gly Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Asn Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Glu Val Ile Leu Gly Gly Gly Ala Asp Gln Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 181
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-H1

<400> 181

Ser Ser Gly Tyr Tyr Trp Gly
1 5

<210> 182
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-H2

<400> 182

Asp Ile Tyr Tyr Thr Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1 5 10 15

<210> 183
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-H3

<400> 183

Glu Glu Val Ile Leu Gly Gly Gly Ala Asp Gln
1 5 10

<210> 184
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E VH region

<400> 184

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Glu Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 185
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-H1

<400> 185

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 186
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-H2

<400> 186

Asp Ile Asn Tyr Ile Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 187
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-H3

<400> 187

Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Glu
1 5 10

<210> 188
<211> 121

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C VH region

<400> 188

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Ala Val Met Tyr Gly Gly Gly Ser Asp Asn Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 189
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-H1

<400> 189

Ser Gly Ser Tyr Tyr Trp Gly
1 5

<210> 190
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-H2

<400> 190

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 191
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-H3

<400> 191

Gln Ala Val Met Tyr Gly Gly Gly Ser Asp Asn
1 5 10

<210> 192
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E VH region

<400> 192

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Asp Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Met Ile Leu Gly Gly Gly Ala Asp Asn Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 193
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-H1

<400> 193

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 194
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-H2

<400> 194

Asp Ile Tyr Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asp
1 5 10 15

<210> 195
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-H3

<400> 195

Glu Asp Met Ile Leu Gly Gly Gly Ala Asp Asn
1 5 10

<210> 196
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B VH region

<400> 196

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 197
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B CDR-H1

<400> 197

Ser Ser Asn Tyr Tyr Trp Gly
1 5

<210> 198
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B CDR-H2

<400> 198

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 199
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B CDR-H3

<400> 199

Glu Ala Val Ser Phe Gly Gly Gly Ala Asp Ser
1 5 10

<210> 200
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E VH region

<400> 200

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Gly
20 25 30

Asn Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

```
Trp Ile Gly Asp Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Met Tyr Gly Gly Gly Gly Asp Ser Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 201
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-H1

<400> 201

```
Ser Gly Asn Tyr Tyr Trp Gly
1               5
```

<210> 202
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-H2

<400> 202

```
Asp Ile Ser Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1               5                   10                  15
```

<210> 203
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-H3

<400> 203

```
Glu Asp Val Met Tyr Gly Gly Gly Gly Asp Ser
1               5                   10
```

<210> 204
<211> 121
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.6A VH region

<400> 204

```
Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1               5                  10                  15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Ser Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 205
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-H1

<400> 205

```
Ser Ser Ser Tyr Tyr Trp Gly
1               5
```

<210> 206
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-H2

<400> 206

```
Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1               5                  10                  15
```

<210> 207
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-H3

<400> 207

Glu Ala Val Ala Leu Gly Gly Gly Ala Asp Ser
1 5 10

<210> 208
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A VH region

<400> 208

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Lys Phe Gly Gly Gly Ala Asp Leu Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 209
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-H1

<400> 209

Ser Ser Ser Tyr Tyr Trp Gly
1 5

<210> 210
<211> 16

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-H2

<400> 210

Asp Ile Asn Tyr Ala Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 211
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-H3

<400> 211

Glu Asp Val Lys Phe Gly Gly Gly Ala Asp Leu
1 5 10

<210> 212
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H VH region

<400> 212

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Asn Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Asn Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 213
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-H1

<400> 213

Ser Gly Ser Tyr Tyr Trp Gly
1 5

<210> 214
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-H2

<400> 214

Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Asn
1 5 10 15

<210> 215
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-H3

<400> 215

Glu Ser Val Pro Leu Gly Gly Gly Ala Asp Asn
1 5 10

<210> 216
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 VL region

<400> 216

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Thr Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr Val Leu
100 105

<210> 217
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-L1

<400> 217

Ser Gly Asp Thr Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 218
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-L2

<400> 218

Glu Asp Ser Glu Arg Pro Ser
1 5

<210> 219
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.13 CDR-L3

<400> 219

Gln Ala Trp Asp Ser Glu Thr Gly Val
1 5

<210> 220
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.16 VL region

<400> 220

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

```
Thr Ala Ser Ile Thr Cys Ser Gly Glu Arg Leu Gly Asp Lys Tyr Val
            20                  25                  30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45

Glu Asp Phe Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
```

<210> 221
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.16 CDR-L1

<400> 221

```
Ser Gly Glu Arg Leu Gly Asp Lys Tyr Val Ser
1               5                   10
```

<210> 222
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.16 CDR-L2

<400> 222

```
Glu Asp Phe Lys Arg Pro Ser
1               5
```

<210> 223
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.16 CDR-L3

<400> 223

```
Gln Ala Trp Asp Arg Asp Thr Gly Val
1               5
```

<210> 224
<211> 106

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 VL region

<400> 224

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Val Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr Val Leu
100 105

<210> 225
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-L1

<400> 225

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 226
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-L2

<400> 226

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 227
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.38 CDR-L3

<400> 227

Gln Ala Trp Asp Arg Asp Val Gly Val
1 5

<210> 228
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 VL region

<400> 228

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 229
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 CDR-L1

<400> 229

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 230
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.4 CDR-L2

<400> 230

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 231
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.4 CDR-L3

<400> 231

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 232
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 VL region

<400> 232

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 233
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-L1

<400> 233

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 234
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-L2

<400> 234

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 235
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.11 CDR-L3

<400> 235

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 236
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 VL region

<400> 236

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 237
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-L1

<400> 237

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 238
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-L2

<400> 238

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 239
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.14 CDR-L3

<400> 239

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 240
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 VL region

<400> 240

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 241
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-L1

<400> 241

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 242
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-L2

<400> 242

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 243
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.17 CDR-L3

<400> 243

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 244
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 VL region

<400> 244

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 245
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-L1

<400> 245

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 246
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-L2

<400> 246

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 247
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.18 CDR-L3

<400> 247

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 248
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 VL region

<400> 248

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 249
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-L1

<400> 249

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 250
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-L2

<400> 250

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 251
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.19 CDR-L3

<400> 251

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 252
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 VL region

<400> 252

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 253
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-L1

<400> 253

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 254
<211> 7

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-L2

<400> 254

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 255
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.22 CDR-L3

<400> 255

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 256
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 VL region

<400> 256

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 257
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-L1

<400> 257

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 258
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-L2

<400> 258

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 259
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.48 CDR-L3

<400> 259

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 260
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 VL region

<400> 260

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 261
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-L1

<400> 261

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 262
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-L2

<400> 262

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 263
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.65 CDR-L3

<400> 263

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 264
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 VL region

<400> 264

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
100 105

<210> 265
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-L1

<400> 265

Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1 5 10

<210> 266
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-L2

<400> 266

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 267
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.66 CDR-L3

<400> 267

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 268
<211> 106
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.71 VL region

<400> 268

```
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                  10                  15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu
            100                 105
```

<210> 269
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 CDR-L1

<400> 269

```
Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala Ser
1               5                  10
```

<210> 270
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 CDR-L2

<400> 270

```
Glu Asp Ser Lys Arg Pro Ser
1               5
```

<210> 271
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 CDR-L3

<400> 271

Gln Ala Trp Asp Arg Asp Thr Gly Val
1 5

<210> 272
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B VL region

<400> 272

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr Val Leu
100 105

<210> 273
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-L1

<400> 273

Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 274
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-L2

<400> 274

Glu Asp Ser Thr Arg Pro Ser
1 5

<210> 275
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.2B CDR-L3

<400> 275

Gln Ala Trp Asp Ser Glu Thr Gly Val
1 5

<210> 276
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F VL region

<400> 276

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Met Glu Ala Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr Val Leu
100 105

<210> 277
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-L1

<400> 277

Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 278
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-L2

<400> 278

Glu Asp Ser Gln Arg Pro Ser
1 5

<210> 279
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1F CDR-L3

<400> 279

Gln Ala Trp Asp Met Glu Ala Gly Val
1 5

<210> 280
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C VL region

<400> 280

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Ser Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 281
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-L1

<400> 281

Ser Gly Asp Ser Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 282
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-L2

<400> 282

Glu Asp Ser Glu Arg Pro Ser
1 5

<210> 283
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10C CDR-L3

<400> 283

Gln Ala Trp Asp Ser Glu Thr Gly Val
1 5

<210> 284
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E VL region

<400> 284

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ala Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 285
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-L1

<400> 285

Ser Gly Glu Gly Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 286
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-L2

<400> 286

Glu Asp Ser Glu Arg Pro Ser
1 5

<210> 287
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10E CDR-L3

<400> 287

Gln Ala Trp Asp Ser Glu Ala Gly Val
1 5

<210> 288
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E VL region

<400> 288

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ala Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 289
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-L1

<400> 289

Ser Gly Asp Arg Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 290
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-L2

<400> 290

Glu Asp Ser Glu Arg Pro Ser
1 5

<210> 291
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7E CDR-L3

<400> 291

Gln Ala Trp Asp Ser Glu Ala Gly Val
1 5

<210> 292
<211> 104

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E VL region

<400> 292

```
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Met Leu Gly Asp Lys Tyr Val
            20                  25                  30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45

Glu Asp Ser Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
                85                  90                  95

Phe Gly Ser Gly Thr Lys Val Thr
            100
```

<210> 293
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-L1

<400> 293

```
Ser Gly Asp Met Leu Gly Asp Lys Tyr Val Ser
1               5                   10
```

<210> 294
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-L2

<400> 294

```
Glu Asp Ser Gln Arg Pro Ser
1               5
```

<210> 295
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.5E CDR-L3

<400> 295

Gln Ala Trp Asp Ser Glu Thr Gly Val
1 5

<210> 296
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B VL region

<400> 296

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Gly Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Ser Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 297
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B CDR-L1

<400> 297

Ser Gly Asp Gly Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 298
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9.12B CDR-L2

<400> 298

Glu Asp Ser Thr Arg Pro Ser
1 5

<210> 299
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.12B CDR-L3

<400> 299

Gln Ala Trp Asp Ser Glu Ser Gly Val
1 5

<210> 300
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H VL region

<400> 300

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 301
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-L1

<400> 301

Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 302
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-L2

<400> 302

Glu Asp Ser Lys Arg Pro Ser
1 5

<210> 303
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.10H CDR-L3

<400> 303

Gln Ala Trp Asp Gly Glu Thr Gly Val
1 5

<210> 304
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A VL region

<400> 304

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Met Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Thr Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 305
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-L1

<400> 305

Ser Gly Asp Met Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 306
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-L2

<400> 306

Glu Asp Thr Asn Arg Pro Ser
1 5

<210> 307
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.6A CDR-L3

<400> 307

Gln Ala Trp Asp Ser Glu Thr Gly Val
1 5

<210> 308
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A VL region

<400> 308

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Met Glu Thr Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 309
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-L1

<400> 309

Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 310
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-L2

<400> 310

Gln Asp Ala Met Arg Pro Ser
1 5

<210> 311
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.7A CDR-L3

<400> 311

Gln Ala Trp Asp Met Glu Thr Gly Val
1 5

<210> 312
<211> 104
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H VL region

<400> 312

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Glu Val Gly Val
85 90 95

Phe Gly Ser Gly Thr Lys Val Thr
100

<210> 313
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-L1

<400> 313

Ser Gly Glu Ser Leu Gly Asp Lys Tyr Val Ser
1 5 10

<210> 314
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-L2

<400> 314

Glu Asp Ser Met Arg Pro Ser
1 5

<210> 315
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.8H CDR-L3

<400> 315

Gln Ala Trp Asp Ser Glu Val Gly Val
1 5

<210> 316
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3 VH region

<400> 316

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Ile Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 317
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.K30 VH region

<400> 317

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 318
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.K42 VH region

<400> 318

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Met Ile Ser Tyr Asp Gly Thr Ile Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 319
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.9A VH region

<400> 319

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Thr Ile Ser Tyr Asp Gly Arg Asn Lys Asp Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 320
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.8A VH region

<400> 320

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 321
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.1A VH region

<400> 321

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe His Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Met Ile Ser Asp Asp Gly Arg Asn Lys Asp Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ala Ala Gly Gly Asn Val Gly Leu Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 322
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.5D VH region

<400> 322

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Val Asp Gly Ser Asn Lys Tyr Ser Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ala Ala Gly Gly Asn Val Gly Leu Asp Ser Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 323
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3A VH region

<400> 323

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 324
<211> 119

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.6B VH region

<400> 324

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Ser Asp Gly Arg Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 325
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3D VH region

<400> 325

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Gln Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Ala Ala Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 326
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.4C VH region

<400> 326

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser His
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Asp Ile Ser Asn Asp Gly Arg Tyr Ala Tyr Ser Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Leu Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Ala Gly Gly Gly Asn Val Gly Phe Asp Ile Trp Gly Gln Gly
100 105 110

Thr Met Val Thr Val Ser Ser
115

<210> 327
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3 VL region

<400> 327

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65 70 75 80

Asp Glu Ala Asp Tyr Leu Cys Gln Ser Trp Asp Arg Ser Asp Val Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 328
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.L45 VL region

<400> 328

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Glu Leu Gly Thr Gln Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Ser Gly Val Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 329
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.L73 VL region

<400> 329

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Asp Asn Leu Gly Ser Gln Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Gln Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Ser Gly Val Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 330
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3A VL region

<400> 330

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Glu Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Ala Thr Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Ser Ser Gly Ala Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 331
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.6B VL region

<400> 331

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Asn Gln Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Gly Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Trp Ser Gly Glu Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 332
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.3D VL region

<400> 332

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Lys Leu Gly Thr Lys Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Gly Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Trp Asp Gln Ser Gly Ala Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 333
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody A10.4C VL region

<400> 333

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Ala Asp Asn Leu Gly Asn Gln Tyr Val
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Gln Asp Gly Met Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Gly Ala Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> 334
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1 VH region

<400> 334

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

```
Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65                  70                  75                  80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 335
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.1 VL region

<400> 335

```
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                   10                  15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95

Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
            100                 105
```

<210> 336
<211> 121
<212> PRT
<213> Artificial Sequence

<220>

<223> DLL4 antibody E9-SE1 VH region

<400> 336

```
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                  10                  15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65                  70                  75                  80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
```

<210> 337
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE1 VL region

<400> 337

```
Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1               5                  10                  15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
            20                  25                  30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
        35                  40                  45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
    50                  55                  60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95
```

Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
100 105

<210> 338
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE2 VH region

<400> 338

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 339
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE2 VL region

<400> 339

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
100 105

<210> 340
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE3 VH region

<400> 340

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 341
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE3 VL region

<400> 341

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Arg Val Thr Val Leu Gly
100 105

<210> 342
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE4 VH region

<400> 342

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 343
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE4 VL region

<400> 343

Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65 70 75 80

Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
100 105

<210> 344
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE5 VH region

<400> 344

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 345
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE5 VL region

<400> 345

Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
20 25 30

Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
35 40 45

Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65 70 75 80

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
85 90 95

Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 346
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE6 VH region

<400> 346

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 347
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE6 VL region

<400> 347

Leu Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Thr Met
65 70 75 80

Asp Glu Ala Asp Tyr Leu Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly
100 105

<210> 348
<211> 121

<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE7 VH region

<400> 348

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Ser Phe
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 349
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE7 VL region

<400> 349

Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
20 25 30

Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
35 40 45

Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65 70 75 80

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
85 90 95

Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 350
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE8 VH region

<400> 350

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Gly Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Tyr Leu Lys Leu Ser Ser Val Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 351
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-SE8 VL region

<400> 351

Glu Tyr Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys
1 5 10 15

Glu Lys Val Thr Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
20 25 30

```
Ala Ser Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Val Ile
        35                  40                  45

Tyr Glu Asp Ser Lys Arg Pro Ser Gly Val Pro Ser Arg Phe Ser Gly
    50                  55                  60

Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Asn Ser Leu Glu Ala
65                  70                  75                  80

Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
                85                  90                  95

Val Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
            100                 105
```

<210> 352
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-FR1 VH region

<400> 352

```
Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu
1               5                   10                  15

Ser Leu Lys Ile Ser Cys Lys Val Ser Gly Gly Ser Ile Ser Ser Ser
            20                  25                  30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Met Pro Gly Lys Gly Leu Glu
        35                  40                  45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
    50                  55                  60

Leu Lys Ser Gln Val Thr Ile Ser Val Asp Thr Ser Phe Asn Thr Phe
65                  70                  75                  80

Phe Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr
                85                  90                  95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
            100                 105                 110

Gln Gly Thr Met Val Thr Val Ser Ser
        115                 120
```

<210> 353
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-FR1 VL region

<400> 353

Glu Tyr Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly
1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
20 25 30

Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Val Ile
35 40 45

Tyr Glu Asp Ser Lys Arg Pro Ser Asp Ile Pro Ala Arg Phe Ser Gly
50 55 60

Ser Asn Ser Gly Asp Glu Ala Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80

Glu Asp Phe Ala Val Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
85 90 95

Val Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg
100 105

<210> 354
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-FR2 VH region

<400> 354

Glu Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Glu Asp Val Ile Leu Arg Gly Gly Ser Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 355
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9-FR2 VL region

<400> 355

Asp Tyr Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr
20 25 30

Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Val Ile
35 40 45

Tyr Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly
50 55 60

Ser Asn Ser Gly Asp Asp Ala Thr Leu Thr Ile Ser Ser Leu Gln Ala
65 70 75 80

Glu Asp Val Ala Val Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly
85 90 95

Val Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105

<210> 356
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 VH region

<400> 356

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 357
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71 VL region

<400> 357

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Tyr Gly Thr Lys Val Thr Val Leu Gly
100 105

<210> 358
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71(M) VH region

<400> 358

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Ala Leu Ala Met Gly Gly Gly Ser Asp Lys Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 359
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71(M) VL region

<400> 359

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
85 90 95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105

<210> 360
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71(L) VH region

<400> 360

Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30

Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35 40 45

Trp Ile Gly Asp Ile Tyr Tyr Thr Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gln Ala Leu Ala Leu Gly Gly Gly Ser Asp Lys Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 361
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> DLL4 antibody E9.71(L) VL region

<400> 361

Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15

Thr Ala Ser Ile Thr Cys Ser Gly Gln Arg Leu Gly Asp Lys Tyr Ala
20 25 30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45

Glu Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60

```
Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Pro Met
65                  70                  75                  80

Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Arg Asp Thr Gly Val
                85                  90                  95

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
            100                 105
```

<210> 362
<211> 19
<212> PRT
<213> Homo sapiens

<400> 362

```
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Gly
1               5                   10                  15

Ser Trp Ala
```

<210> 363
<211> 19
<212> PRT
<213> Homo sapiens

<400> 363

```
Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Arg
1               5                   10                  15

Val Trp Ala
```

<210> 364
<211> 19
<212> PRT
<213> Homo sapiens

<400> 364

```
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15

Ser Glu Ala
```

<210> 365
<211> 19
<212> PRT
<213> Homo sapiens

<400> 365

```
Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1               5                   10                  15
```

Ser Glu Ala

<210> 366
<211> 22
<212> PRT
<213> Homo sapiens

<400> 366

Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1 5 10 15

Phe Pro Gly Ala Arg Cys
20

<210> 367
<211> 22
<212> PRT
<213> Homo sapiens

<400> 367

Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1 5 10 15

Phe Pro Gly Ala Arg Cys
20

<210> 368
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> E9.71(M) antibody cleavage site

<400> 368

Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Gly
1 5 10 15

Ser Trp Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
20 25 30

<210> 369
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> E9.71(M)-1 antibody cleavage site

<400> 369

Met Ala Trp Ser Pro Leu Phe Leu Thr Leu Ile Thr His Cys Ala Arg
1 5 10 15

Val Trp Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
20 25 30

<210> 370
<211> 30
<212> PRT
<213> Artificial Sequence

<220>
<223> E9.71(M)-2 antibody cleavage site

<400> 370

Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1 5 10 15

Ser Glu Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
20 25 30

<210> 371
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<223> E9.71(M)-3 antibody cleavage site

<400> 371

Met Ala Trp Thr Pro Leu Leu Leu Pro Leu Leu Thr Phe Cys Thr Val
1 5 10 15

Ser Glu Ala Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
20 25

<210> 372
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> E9.71(M)-4 antibody cleavage site

<400> 372

Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1 5 10 15

Phe Pro Gly Ala Arg Cys Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val
20 25 30

Ser

<210> 373
<211> 32
<212> PRT
<213> Artificial Sequence

<220>

<223> E9.71(M)-5 antibody cleavage site

<400> 373

Met Asp Met Arg Val Pro Ala Gln Arg Leu Gly Leu Leu Leu Leu Trp
1 5 10 15

Phe Pro Gly Ala Arg Cys Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser
20 25 30

<210> 374
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR localization peptide

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X can be any amino acid

<400> 374

Phe Gly Xaa Gly
1

<210> 375
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR localization peptide

<220>
<221> misc_feature
<222> (2)..(9)
<223> X can be any amino acid, positions 2-9

<400> 375

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 376
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR localization peptide

<400> 376

Leu Glu Trp Ile Gly
1 5

<210> 377
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR localization peptide

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X can be any amino acid

<400> 377

Trp Gly Xaa Gly
1